BusinessJun 11, 2026, 12:00 PM

How a Google DeepMind Spin-off Hunts Hidden Drug Targets

TickrWire Editorial Desk·Jun 11, 2026, 12:00 PM·1 min read AI-assisted, human-reviewed

Reported by IEEE Spectrum AI: How a Google DeepMind Spin-off Hunts Hidden Drug Targets. Analysis and context written by TickrWire.

30-second summary

Isomorphic Labs, a Google DeepMind spin-off, advances AI-driven drug discovery by leveraging protein structure prediction to sign major drug-discovery partnerships.

TickrWire
How a Google DeepMind Spin-off Hunts Hidden Drug Targets
Full story

For more than a decade, artificial intelligence has been touted as a way to dramatically accelerate drug discovery. Yet despite billions of dollars in investment, relatively few AI-designed medicines have made it to patients. That’s partially because the timelines for careful drug testing can’t be easily compressed—and partially because drug development is just really hard.

Isomorphic Labs, the Google DeepMind spin-off that’s building on DeepMind’s Nobel Prize-winning work on protein structure prediction, may be making the most progress. The company has signed major drug-discovery partnership

Sources · 1
Read next
More stories